A phase Ib single-arm trial of bintrafusp alfa (BA) for pretreated, locally advanced/unresectable or metastatic (advanced) urothelial cancer (aUC)

被引：0

作者：

Grivas, P. ^{[1
]}

Sridhar, S. ^{[2
]}

Perez Valderrama, B. ^{[3
]}

Castellano Gauna, D. E. ^{[4
]}

Loriot, Y. ^{[5
]}

Doger de Speville, B. ^{[6
]}

Pouessel, D. ^{[7
]}

van der Heijden, M. S. ^{[8
]}

Galsky, M. D. ^{[9
]}

Gulati, S. ^{[10
]}

Ravaud, A. ^{[11
]}

Fontana, E. ^{[12
]}

Spira, A. I. ^{[13
]}

Gartrell, B. A. ^{[14
]}

Mortazavi, A. ^{[15
]}

Isambert, N. ^{[16
]}

Baxter, D. ^{[17
]}

Powles, T. B. ^{[18
]}

Khaled, A. H. ^{[19
]}

Morales Barrera, R. ^{[20
]}

机构：

[1] Univ Washington, Dept Med Oncol, Seattle Canc Care Alliance, Seattle, WA USA

[2] UHN, Dept Med Oncol, Princess Margaret Canc Ctr, Toronto, ON, Canada

[3] Hosp Univ Virgen del Rocio, Dept Med Oncol, Seville, Spain

[4] Hosp Univ 12 Octubre, Dept Med Oncol, Madrid, Spain

[5] Inst Gustave Roussy, Dept Canc Med, Villejuif, France

[6] Univ Hosp Fdn Jimenez Diaz, Start Madrid Phase 1 Unit, Madrid, Spain

[7] Icr Iuct Oncopole, Dept Med Oncol, Toulouse, France

[8] Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands

[9] Icahn Sch Med, Tisch Canc Inst, Mt Sinai Hosp, New York, NY USA

[10] UC Davis Comprehens Canc Ctr, Hematol & Oncol Dept, Sacramento, CA USA

[11] CHU Bordeaux Hop St Andre, Dept Med Oncol, Bordeaux, France

[12] Sarah Cannon Res Inst SCRI UK, Drug Dev, London, England

[13] Virginia Canc Specialist, Res Inst, Fairfax, VA USA

[14] Montefiore Einstein Ctr Canc Care, Oncol & Urol, Bronx, NY USA

[15] Ohio State Univ, Med Oncol Dept, Wexner Med Ctr, Columbus, OH USA

[16] CHU Poitiers, Dept Med Oncol, Jean Bernard Hop, Poitiers, France

[17] GSK USA, Collegeville, PA USA

[18] St Bartholomews Hosp Barts Hlth NHS Trust, Dept Oncol, London, England

[19] GSK USA, Dept Oncol, Collegeville, PA USA

[20] Vall dHebron Univ Hosp, Dept Med Oncol, Barcelona, Spain

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.1023

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2374P

引用

页码：S1209 / S1210

页数：2

共 50 条

[31] A phase II trial of regorafenib for advanced urothelial cancer (aUC) following prior chemotherapy
Naik, Gurudatta
Vaishampayan, Ulka N.
Nabell, Lisle
De Shazo, Mollie R.
Nandagopal, Lakshminarayanan
Grivas, Petros
Morgan, Charity
Hardwick, Pamela
Sonpavde, Guru
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[32] ONCOLOGISTS' PREFERENCES FOR FIRST-LINE (1L) TREATMENT OF LOCALLY ADVANCED/ UNRESECTABLE OR METASTATIC UROTHELIAL CARCINOMA (AUC)
Grivas, P.
Phani, V
Chiu, K.
Pawar, V
Chang, J.
Bharmal, M.
VALUE IN HEALTH, 2022, 25 (01) : S162 - S162
[33] Neoadjuvant camrelizumab plus chemotherapy for locally advanced cervical cancer (NACI study): A prospective, single-arm, phase II trial
Chen, Jing
Li, Kezhen
Hu, Yingjie
Han, Yingyan
Shen, Yuanming
Wang, Yanzhou
Song, Kun
Xia, Bairong
Chen, Xiaojun
Zou, Dongling
Wang, Yingmei
Sun, Chaoyang
Chen, Gang
Ma, Ding
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[34] Neoadjuvant tislelizumab plus chemotherapy among patients with locally advanced cervical cancer: A prospective, single-arm, phase II trial
Sheng, Jindong
Liu, Wenxin
Liu, Ruoyan
Liu, Chunyan
Wang, Bochang
Liu, Xiangyu
Xu, Changxiao
Fu, Xin
Wang, Ke
GYNECOLOGIC ONCOLOGY, 2024, 190 : S14 - S14
[35] Donafenib as neoadjuvant therapy in locally advanced thyroid cancer: protocol for the DONATHYCA phase II prospective single-arm trial in China
Yu, Jianhong
Liu, Hui
Wu, Yu
BMJ OPEN, 2024, 14 (05):
[36] Neoadjuvant chemotherapy plus camrelizumab for locally advanced cervical cancer (NACI study): a multicentre, single-arm, phase 2 trial
Li, Kezhen
Chen, Jing
Hu, Yingjie
Wang, Yan-Zhou
Shen, Yuanming
Chen, Gang
Peng, Wenju
Fang, Zixuan
Xia, Bairong
Chen, Xiaojun
Song, Kun
Wang, Yingmei
Zou, Dongling
Wang, Yan-Chun
Han, Yingyan
Feng, Xue
Yuan, Jing
Guo, Shuaiqingying
Meng, Xiaolin
Feng, Chenzhao
Chen, Yin
Yang, Jie
Fan, Junpeng
Wang, Jianliu
Ai, Jihui
Ma, Ding
Sun, Chaoyang
LANCET ONCOLOGY, 2024, 25 (01): : 76 - 85
[37] Neoadjuvant camrelizumab plus chemotherapy in patients with locally advanced cervical cancer (NACI): A prospective, single-arm, phase II trial
Chen, J.
Li, K.
Han, Y.
Shen, Y.
Wang, Y.
Song, K.
Chen, X.
Xia, B.
Zou, D.
Wang, Y.
Ma, D.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S804 - S804
[38] Induction Toripalimab and Chemotherapy for Organ Preservation in Locally Advanced Laryngeal and Hypopharyngeal Cancer: A Single-Arm Phase II Clinical Trial
Ou, Xiaomin
Zhai, Ruiping
Wei, Wenjun
Chen, Jiaying
Ou, Dan
Liao, Tian
Xu, Tingting
Zhu, Yongxue
Wang, Yulong
Huang, Shenglin
Shi, Rongliang
Wu, Bin
Chen, Tongzhen
Li, Yuan
Yang, Zhongyi
Zhou, Changming
Liu, Yuan
Jiang, Ziting
Zeng, Min
Liu, Xin
Ji, Dongmei
Ying, Hongmei
Zhang, Zhen
Hu, Chaosu
Lu, Xueguan
Ji, Qinghai
He, Xiayun
Wang, Yu
CLINICAL CANCER RESEARCH, 2024, 30 (02) : 344 - 355
[39] The efficacy and safety of anlotinib in neoadjuvant treatment in locally advanced thyroid cancer: A single-arm phase II clinical trial.
Huang, Naisi
Sun, Guohua
Wang, Yulong
Chen, Jiaying
Guan, Qing
Lu, Zhongwu
Xiang, Jun
Wei, Wenjun
Ma, Ben
Ji, Qinghai
Wang, Yu
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[40] A phase II, multicenter, single-arm trial of eribulin as first-line chemotherapy for HER2-negative locally advanced or metastatic breast cancer
Takashima, Tsutomu
Tokunaga, Shinya
Tei, Seika
Nishimura, Shigehiko
Kawajiri, Hidemi
Kashiwagi, Shinichiro
Yamagata, Shigehito
Noda, Satoru
Nishimori, Takeo
Mizuyama, Yoko
Sunami, Takeshi
Tezuka, Kenji
Ikeda, Katsumi
Ogawa, Yoshinari
Onoda, Naoyoshi
Ishikawa, Tetsuro
Kudoh, Shinzoh
Takada, Minoru
Hirakawa, Kosei
SPRINGERPLUS, 2016, 5 : 1 - 8

← 1 2 3 4 5 →